Hydrochlorothiazide/Triamterene/Dihydralazine Sulfate/Reserpine

氢氯噻嗪/氨苯蝶啶/硫酸双肼屈嗪/利血平

Report date: 2022/03/10 13:31:40

NME

Base Information

Drug NameHydrochlorothiazide/Triamterene/Dihydralazine Sulfate/Reserpine

Drug Alias Name复方利血平氨苯蝶啶

ClassificationSmall molecules

Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsSynaptic vesicular amine transporter inhibitorsSodium channel alpha subunit blockers

TargetsThiazide-sensitive sodium-chloride cotransporterSodium channel alpha subunitSynaptic vesicular amine transporter

Therapy Area/IndicationsHypertension

Global Approved IndicationsHypertension

Approved Indications in ChinaHypertension

Original Approved Country/TerritoryMainland China

Original Approved Date2015/08/04

Country/TerritoryMainland China

CombinationsYes Hydrochlorothiazide Triamterene Dihydralazine Sulfate

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesChina Resources Double-Crane Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsHypertension

Inactive IndicationsN/A

Other Information

ATC CodeC03AX01